Low Density Lipoprotein (LDL) News and Research

RSS

Generics as a way to lower health care costs

As the nation seeks to expand health care coverage to more citizens without adding burdensome costs, researchers from Harvard University, Brigham and Women's Hospital and CVS Caremark reported that preventative health care may be significantly less costly than previously thought, due to expanded use of cost-effective generic medications for the treatment and prevention of chronic disease.

8 Jul 2011

EAS, ESC develop new European guidelines to manage dyslipidaemias

Cardiovascular disease (CVD), driven by the global pandemics of obesity and diabetes, poses a daunting challenge to clinicians in the 21st century. Despite progress, there is still much to be done to improve the control of dyslipidaemia, a key risk factor.

28 Jun 2011

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced new data from a Phase 1b study of ZGN-433, a selective methionine aminopeptidase 2 inhibitor (MetAP2), which showed a significant improvement in cardiovascular risk markers in severely obese subjects.

27 Jun 2011

High dose statins raise risk of diabetes: Study

According to the latest research taking a high-dose statin to lower cholesterol may increase risk of developing diabetes by as much as 12 percent, but the heart benefits of statins still outweigh the risks.

23 Jun 2011

Maternal smoking 'imprints' unhealthy set of characteristics on unborn babies

Researchers in Australia have discovered that mothers who smoke during pregnancy are causing developmental changes to their unborn babies that lead to them having lower levels of the type of cholesterol that is known to protect against heart disease in later life - high-density lipoprotein (HDL) cholesterol.

22 Jun 2011

Positive results from LCP-Tacro Phase III trial in stable kidney transplant recipients

LifeCycle Pharma A/S today reported that the company's lead product candidate, LCP-Tacro, successfully demonstrated non-inferiority compared to tacrolimus in its Phase III trial, Study 3001.

21 Jun 2011

Larger trial study needed to decide fate of niacin

Niaspan is a cholesterol drug manufactured by Abbott Laboratories. Doctors have customarily prescribed Niacin to raise levels of HDL ("good" cholesterol) in patients taking a statin pill that is successfully lowering their LDL ("bad" cholesterol).

10 Jun 2011

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

Merck, known as MSD outside the United States and Canada, today announced changes to the prescribing information in the United States for the highest dose of simvastatin, 80 mg, and the use of simvastatin with certain other medicines.

9 Jun 2011

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

The U.S. Food and Drug Administration today is announcing safety label changes for the cholesterol-lowering medication simvastatin because the highest approved dose--80 milligram (mg)--has been associated with an elevated risk of muscle injury or myopathy, particularly during the first 12 months of use.

9 Jun 2011

'Ultra-bad' cholesterol increases risk of heart disease in people with type 2 diabetes

Scientists from the University of Warwick have discovered why a newly found form of cholesterol seems to be 'ultra-bad', leading to increased risk of heart disease. The discovery could lead to new treatments to prevent heart disease particularly in people with type 2 diabetes and the elderly.

30 May 2011

Obesity and insulin resistance are a greater risk for fatty liver than previously thought

Being overweight and resistant to insulin constitute a greater risk for fatty liver than was previously thought, according to a study from Linköping University in Sweden that is now being published in the journal Annals of Medicine.

30 May 2011

Lipidomic profiling can lead to better and earlier prediction of major diseases

Studying the genetic make-up of different varieties of lipids in the blood plasma of an individual can lead to a better and earlier prediction of diseases such as diabetes, atherosclerosis, and heart disease, two researchers will tell the annual conference of the European Society of Human Genetics today.

30 May 2011

Cholesterol drug Niaspan fails to protect heart: Study

According to researchers at the National Heart, Lung, and Blood Institute (NHLBI), increasing the dose of niacin to patients with heart disease who are already taking a cholesterol-lowering statin does nothing extra to prevent heart attacks and strokes. Approximately one out of seven Americans have high blood cholesterol, a main risk factor in heart disease, which kills some 800,000 people in the United States annually.

29 May 2011

Ultra bad cholesterol

Bad cholesterol, known as LDL is known to be sticky but this ultra –bad called MGmin-LDL is found to be stickier meaning it's more likely to attach to arterial walls. This is more dangerous because when LDL attaches to artery walls it forms fatty plaques that cause coronary heart disease (CHD). As fatty plaques grow, they narrow the arteries and reduce blood flow and also may trigger a stroke or heart attack. CHD is the most common type of heart disease and kills almost 450,000 Americans each year.

29 May 2011

Efficacy of Abbott cholesterol drug in question

A latest study has found that using medication to raise good cholesterol while lowering the bad does NOT translate into fewer adverse cardiovascular events like heart attacks and strokes. The study was revealed Thursday by the National Institutes of Health and it found that high dosages of Abbott Laboratories' Niaspan failed to prevent heart attacks and boosted the likelihood of a stroke when combined with the popular generic cholesterol pill Simvastatin, also known under the brand name Zocor.

29 May 2011

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

The National Heart, Lung and Blood Institute (NHLBI), a division of the National Institutes of Health (NIH), disclosed results from an interim analysis of the AIM-HIGH clinical trial.

27 May 2011

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

The National Heart, Lung, and Blood Institute of the National Institutes of Health has stopped a clinical trial studying a blood lipid treatment 18 months earlier than planned. The trial found that adding high dose, extended-release niacin to statin treatment in people with heart and vascular disease, did not reduce the risk of cardiovascular events, including heart attacks and stroke.

27 May 2011

Studies consistently confirm health benefits of fruit consumption

What do apples, blueberries and prunes have in common? If you guessed that they are all fruits you would be correct. However, that would only be scratching the surface. The fact is that studies consistently confirm the benefits of eating a variety of fruit daily. These benefits include better blood profiles, increased bone density and a strong defense against obesity.

24 May 2011

New study raises doubts about benefits of ezetimibe in patients suffering from high LDL cholesterol

More than 42 million Americans suffer from high cholesterol, and 63 million more have borderline high cholesterol. Over time, high levels of LDL cholesterol, often called "bad cholesterol," build up along the walls of arteries and blood vessels, a process called atherosclerosis, which can lead to a high risk of heart disease, stroke and heart attack.

21 May 2011

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

The U.S. Food and Drug Administration today held an Endocrinologic and Metabolic Drugs Advisory Committee to review the results of the ACCORD Lipid study as they relate to the use of fenofibric acid (sold as Trilipix in the United States) in combination with a statin in patients with mixed dyslipidemia and at high risk of heart disease.

20 May 2011

Low Density Lipoprotein (LDL) News and Research

Generics as a way to lower health care costs

EAS, ESC develop new European guidelines to manage dyslipidaemias

New data from Zafgen's ZGN-433 Phase 1b study on obesity presented at ADA 2011

High dose statins raise risk of diabetes: Study

Maternal smoking 'imprints' unhealthy set of characteristics on unborn babies

Positive results from LCP-Tacro Phase III trial in stable kidney transplant recipients

Larger trial study needed to decide fate of niacin

Merck announces changes to high-dose simvastatin prescribing information in the U.S.

U.S. FDA announces safety label changes for cholesterol-lowering medication, simvastatin

'Ultra-bad' cholesterol increases risk of heart disease in people with type 2 diabetes

Obesity and insulin resistance are a greater risk for fatty liver than previously thought

Lipidomic profiling can lead to better and earlier prediction of major diseases

Cholesterol drug Niaspan fails to protect heart: Study

Ultra bad cholesterol

Efficacy of Abbott cholesterol drug in question

Interim analysis of AIM-HIGH study affirms positive impact of Niaspan on HDL and triglyceride lipid values

NHLBI stops AIM-HIGH combination clinical trial in high blood cholesterol

Studies consistently confirm health benefits of fruit consumption

New study raises doubts about benefits of ezetimibe in patients suffering from high LDL cholesterol

Abbott appreciates FDA Advisory Committee recommendations to retain Trilipix indication for mixed dyslipidemia

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News